Raleigh Capital Management Inc. has increased its stake in Kenvue Inc. (NYSE:KVUE), while other firms like Chelsea Counsel Co. and Caas Capital Management LP have sold their shares. Johnson & Johnson is also exiting its investment in Kenvue. The bio-tech company's recent Q1 2024 earnings call was noted. It is also observed that Kenvue's earnings results are not reflecting the complete picture. A 4% yield in Kenvue shares has crossed the mark, encouraging investors to take long-term positions. However, Kenvue's stock hit a new 52-week low at $17.75, with companies including Chilton Investment Co. Inc. and Bridgewater Associates LP acquiring significant shares. There are questions regarding Kenvue's plans to invest in product development and marketing. Layoffs in 2024 demonstrate the company's cost-cutting measures. Its recent performance has been labeled as 'woeful' with 'worst-in-class' growth. Nonetheless, amidst fluctuations, American International Group Inc. has reduced its position in Kenvue. The stock jumped 2% after earnings beat estimates. Additional announcements include pricing for secondary stock offering as Johnson & Johnson exits and the launch of a secondary offering.
Kenvue KVUE News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sun, 16 Jun 2024 14:56:19 GMT -
Rating -2
- Innovation -4
- Information 6
- Rumor 4
